My research interest is in the early diagnosis of acute coronary syndromes, particularly with biomarkers. I am internationally renowned for my work with high sensitivity cardiac troponin. My methodological expertise is in clinical epidemiology (with interests in diagnostics, cohort studies and late phase clinical trials) and analytical modelling (particularly the derivation, validation and implementation of novel technology to support clinical decision making).
I am currently Chief Investigator for:
- The Bedside Evaluation of Sensitive Troponin (BEST) Study. This large cohort study (n=1,575; recruitment in progress) essentially represents a programme of research with six separate workstreams incorporating two PhDs, a H2020 project grant, a project grant from the Royal College of Emergency Medicine and a research grant from Abbott Point of Care. In this study we will evaluate:
- The diagnostic accuracy of point of care troponin testing within 3 hours of arrival in the Emergency Department
- The diagnostic accuracy of point of care heart-type fatty acid binding protein (H-FABP) testing in the Emergency Department
- The accuracy of the Manchester Acute Coronary Syndromes (MACS) prediction model and the HEART score
- A novel prediction model to optimise electrocardiographic (ECG) diagnosis of acute coronary syndromes
- Highly sensitive and super sensitive cardiac troponin assays for the diagnosis of acute coronary syndromes
- A pilot randomised controlled trial of the Manchester Acute Coronary Syndromes Decision Rule. Feasibility study & pilot randomised controlled trial at two centres. (Write up phase)
I am currently Principal Investigator for:
- The CAMEO trial: icatibant for the treatment of ACE-inhibitor induced angio-oedema. Multi-centre, international randomised controlled trial, sponsored by Shire. Write up phase.
- The TRAPID-AMI study, a multinational, industry sponsored prospective cohort study designed to evaluate a novel algorithm to enable early exclusion of acute coronary syndromes. Write up phase. [UK Chief Investigator]
- Efficacy and safety of relaxin for the treatment of acute heart failure (RELAX-2 AHF). Multicentre randomised controlled trial, sponsored by Novartis.
- The CRASH-3 trial: randomised controlled trial comparing tranexamic acid to placebo for traumatic brain injury
- The DiPEP (Diagnosis of Pulmonary Embolism in Pregnancy) study. Cohort study
- The Pandemic Influenza Triage in the Emergency Department (PAINTED) study.Prospective cohort study, sponsored by The University of Sheffield, funded by NIHR.